1. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
- Author
-
Chiao Lo, Huo-Mu Chen, Po-Han Lin, Wen-Lin Kuo, Yen-Shen Lu, Peng-Chan Lin, Chiun-Sheng Huang, Ai-Chu Huang, Kuo-Chih Cheng, Dah-Cherng Yeh, Chunyu Liu, Tsu Yi Chao, Wen-Hung Kuo, King-Jen Chang, Liang-Chih Liu, Shin-Cheh Chen, Ching-Hung Lin, Ling-Ming Tseng, Hui-Chen Wu, Ming-Yang Wang, Karen Yang, and Yuan-Ching Chang
- Subjects
Adult ,BRCA2 Protein ,Oncology ,Heterozygote ,medicine.medical_specialty ,Cancer Research ,BRCA1 Protein ,business.industry ,BRCA mutation ,Breast Neoplasms ,Triple Negative Breast Neoplasms ,Middle Aged ,medicine.disease ,Contralateral breast cancer ,Breast cancer ,Internal medicine ,medicine ,Humans ,Female ,Neoplasm Recurrence, Local ,skin and connective tissue diseases ,business ,Germ-Line Mutation - Abstract
Purpose Breast cancer is increasing around the globe, including Asia. We aimed to examine the survival and risk of contralateral breast cancer (CBC) in Asian breast cancer patients with BRCA mutations. MethodsA total of 128 breast cancer patients with germline BRCA mutations and 4,754 control breast cancer patients were enrolled. Data on clinical pathologic characteristics, survival and CBC were collected from the medical record. The rates of survival and CBC were estimated by Kaplan-Meier method. Results The mean age of onset in BRCA mutation carriers was significantly younger than control patients (BRCA vs. Non-BRCA: 43.9 vs. 53.2 years-old). BRCA mutation carriers had a higher proportion of triple-negative breast cancer (TNBC) (52%) than control patients (12%, pBRCA mutation patients than in control cases (hazard ratio (HR) = 3.95, 95% CI 2.71-5.75); when stratified by genotype, the HRs (95%CI) were 4.84 (3.00-7.82) for BRCA1 and 3.13 (1.78-5.49) for BRCA2 carriers, respectively. Moreover, BRCA1 mutation patients with triple-negative breast cancer (TNBC) as their first breast cancer had the highest risk of CBC (HR = 5.55, 95% CI 3.29-9.34). However, we did not observe any differences in relapse-free survival and overall survival between mutation carriers and control patients. ConclusionOur study suggest that BRCA patients had a significantly higher risk of developing CBC, particularly for BRCA1 mutation carriers with TNBC as the first breast cancer.
- Published
- 2022